Effect of glutamine in breast cancer

Effect of glutamine supplementation on cardiomyopathy biomarkers, body composition changes and quality of life in breast cancer patients undergoing chemotherapy: a clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240916063060N1

Enrollment

Registered

2025-01-26

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

????? ?????. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: The intervention group will receive 5 grams of glutamine powder daily for a duration of 8 weeks. Glutamine will be purchased from Karen Company. All patients will b

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Willingness to cooperate Adult women (over 18 years of age) with breast cancer at the beginning of chemotherapy who referred to the Mehraneh Charity Association of Zanjan.

Exclusion criteria

Exclusion criteria: Report of food intake that is too much or too little (4200-800) kcal Body mass index less than 18.5 and more than 45 Drug use or alcohol consumption at least once a week Pregnancy and lactation Having CKD, CAD, MI, ESRD, DM, Liver disease

Design outcomes

Primary

Measure	Time frame
Serum cTnT level. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: ELISA.;Serum CK-MB level. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: ELISA.;Echocardiography test. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Echocardiography device.;Body composition analysis. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Body composition analyzer.;Food frequency. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Food frequency questionnaire.;Anthropometric index(weight, height, and Body Mass Index). Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Scale and Stadiometer.	—

Measure

Time frame

Serum cTnT level. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: ELISA.;Serum CK-MB level. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: ELISA.;Echocardiography test. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Echocardiography device.;Body composition analysis. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Body composition analyzer.;Food frequency. Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Food frequency questionnaire.;Anthropometric index(weight, height, and Body Mass Index). Timepoint: Before the start of the study and 2 months after the intervention. Method of measurement: Scale and Stadiometer.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Questionnaire (QLQ-C30).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmadreza Rasouli

Tabriz University of Medical Sciences

ahmadrasoulinut@yahoo.com+98 24 3356 1790

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026